On Monday, Jefferies initiated coverage on Qiagen NV (NYSE:QGEN) by assigning a Buy rating and setting a price target of $54.00. Currently trading at $44.32 with a market capitalization of $9.86 billion, Qiagen is a provider of sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research, recognized for its robust portfolio in the healthcare sector, including biotechnology, genomics research, and point-of-care diagnostics. According to InvestingPro analysis, the company maintains strong financial health with a comprehensive Fair Value assessment available in the Pro Research Report.
Jefferies highlighted Qiagen's competitive edge with its vast array of products that span sample technology, molecular diagnostics like qPCR and dPCR, and genomic consumables. The company's strong positions in high-margin sample-prep instrumentation and blood-based tuberculosis testing are seen as a solid foundation to support its growth strategy. Qiagen's Five Pillar growth strategy is anticipated to drive double-digit earnings growth through 2028, based on mid to high single-digit top-line growth.
The firm pointed out that Qiagen's current valuation, at approximately 13 times EBITDA, suggests multiple routes for the stock to appreciate. Given the stock's historical discount of 10% relative to the S&P 500 compared to its 10-year average of a 30% premium, Jefferies sees limited downside risk for the stock's multiple, especially with the expected double-digit earnings growth.
After three years of declining revenues, Jefferies believes that Qiagen is positioned for a rebound as it executes its long-range plan that was outlined at the 2024 Capital Markets Day. The analyst anticipates that once growth resumes, investor attention will likely return to Qiagen's core business. While not essential for the stock's performance, the multiple could re-rate based on a pattern of beating and raising estimates or several potential catalysts, including wins in digital PCR, dominance in QuantiFERON tuberculosis tests, and new product introductions.
In conclusion, Jefferies has initiated coverage on Qiagen with a positive outlook, recommending a Buy rating and a $54 price target, reflecting confidence in the company's growth strategy and potential for stock appreciation. InvestingPro data reveals that management has been aggressively buying back shares, and the stock trades with low price volatility. Discover 8 additional exclusive ProTips and comprehensive financial analysis in the full InvestingPro Research Report.
In other recent news, QIAGEN N.V. exceeded third-quarter expectations, reporting sales of $502 million, a 6% growth at constant exchange rates (CER), and an adjusted diluted earnings per share (EPS) of $0.57, surpassing the projected $0.55. The company also upgraded its 2024 adjusted EPS target to $2.19 from $2.16, with an anticipated minimum of $0.60 for Q4 adjusted EPS. Significant growth drivers included the Diagnostic Solutions product group and consumables, with a notable 40% growth in the QIAstat product line.
QIAGEN also confirmed its 2024 sales outlook of at least $1.985 billion. However, the company experienced a slight decline in Digital Insights sales due to a shift towards Software (ETR:SOWGn) as a Service contracts. There was also a 2% drop in sales in the Asia Pacific region, with China experiencing a high single-digit decline.
In other developments, Jonathan Sheldon stepped down as Head of QIAGEN Digital Insights. Furthermore, the company anticipates a 7% compound annual growth rate (CAGR) from 2024 to 2028, and plans to enhance its product portfolio with new launches in 2025 and 2026.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.